Human Phospho-VEGFR3/Flt-4 DuoSet IC ELISA DYC2724-2 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemHuman Phospho-VEGFR3/Flt-4 DuoSet IC ELISA
CompanyR&D Systems, a Bio-Techne Brand
Price $495.00Supplier Page View Company Product Page
Catalog NumberDYC2724-2
NCBI Full Gene Namefms related receptor tyrosine kinase 4
NCBI Gene AliasesCHTD7, FLT-4, FLT41, LMPH1A, LMPHM1, PCL, VEGFR-3, VEGFR3
StorageStore the unopened product at 2 - 8 °C. Do not use past expiration date
Detection TargetVEGFR3/Flt-4
ReactivityHuman
ApplicationsELISA
Quantity1 Kit (for 2 Plates) (also 1 Kit (for 5 Plates))

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Activation of VEGFR3 and MLC2 are critical for GLP-2 enhancement of chylomicron transportGastro Hep AdvancesDecember 27, 2024Lili Tian, Majid Mufaqam Syed-Abdul, Gary F. Lewismeasured by a modified phosphorylation ELISA kit (Human Phospho-VEGFR3/Flt-4 DuoSet IC ELISA, Catalog #: DYC2724-2, R&D system) as per the manufacturer’s instruction. Capture antibody of this human kit was replaced

(2) Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and functionFrontiers in Cell and Developmental BiologySeptember 25, 2023Lorenzo M. Fernandes, Jeffrey Tresemer, Jing Zhang, Jonathan J. Rios, Joshua P. Scallan, Michael T. Dellingercommercially available ELISA kits to measure VEGF-C (R&D Systems, DY752B) and phospho-VEGFR3 (R&D Systems, DYC2724-2) levels. We measured VEGF-C levels in cell lysates and conditioned media from GFP-LECs and KRASG12D-LECs.

(3) Decorin suppresses tumor lymphangiogenesis: A mechanism to curtail cancer progressionbioRxiv : the preprint server for biologyAugust 29, 2023Mondal DK, Xie C, Buraschi S, Iozzo RV.

(4) Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell CarcinomasCellsMay 17, 2021Dumond A, Montemagno C, Vial V, Grépin R, Pagès G.

(5) Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFDThe Journal of clinical investigationJune 1, 2016Bui HM, Enis D, Robciuc MR, Nurmi HJ, Cohen J, Chen M, Yang Y, Dhillon V, Johnson K, Zhang H, et al.

(6) The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biologyThe Journal of biological chemistryMarch 22, 2013Harris NC, Davydova N, Roufail S, Paquet-Fifield S, Paavonen K, Karnezis T, Zhang YF, Sato T, Rothacker J, Nice EC, et al.

(7) Mechanoinduction of lymph vessel expansionThe EMBO journalFebruary 15, 2012Planas-Paz L, Strilić B, Goedecke A, Breier G, Fässler R, Lammert E.

(8) Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesisMolecular cancer therapeuticsJanuary 1, 2009Schomber T, Zumsteg A, Strittmatter K, Crnic I, Antoniadis H, Littlewood-Evans A, Wood J, Christofori G.

Be the First to Write a Review!

Phospho-VEGFR3/Flt-4 ELISA